Background and aims Cannabis products with high delta‐9‐tetrahydrocannabinol (THC)
concentrations carry an increased risk of addiction and mental health disorders, while it has …

Objectives The liberalisation of cannabis laws, the increasing availability and potency of
cannabis has renewed concern about the risk of psychosis with cannabis. Methods The …

BackgroundPrevious research suggests an increase in schizophrenia population
attributable risk fraction (PARF) for cannabis use disorder (CUD). However, sex and age …

Abstract Background and Aims Cannabis products are becoming increasingly diverse, and
vary considerably in concentrations of∆ 9‐tetrahydrocannabinol (THC) and cannabidiol …

Importance Cannabis use is increasing worldwide and is suspected to be associated with
increased risk of psychiatric disorders; however, the association with affective disorders has …

Importance Cannabis use and potency of cannabis have increased during the past 2
decades. If the association between cannabis use and schizophrenia is causal, this should …

Aims To quantify changes in (i) potency (concentration of Δ9‐tetrahydrocannabinol;%
THC),(ii) price (euros/g of cannabis) and (iii) value (mg THC/euro) of cannabis resin and …

Cannabis, a widely used psychoactive substance, can trigger acute cannabis-associated
psychotic symptoms (CAPS) in people who use cannabis (PWUC). To assess rates and …

Cannabis is gaining increasing attention due to the high pharmacological potential and
updated legislation authorizing multiple uses. The development of time-and cost-efficient …

Background The use of cannabis as medicine (CaM) both prescribed and non-prescribed
has increased markedly in the last decade, mirrored in a global shift in cannabis policy …